We are excited to announce that Eagle IP has been named as the winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026.

The LSPN Awards recognize outstanding achievement, innovation, and leadership within the life sciences intellectual property community. The Cross-Border Collaboration Partner of the Year Award honors the non-US law firm that has demonstrated exceptional partnership with US law firms and life sciences companies through superior cross-jurisdictional expertise, strategic counsel, and seamless collaboration.

This award underscores the strength of our team’s commitment to delivering sophisticated, high-quality intellectual property services that effectively bridge Greater China and global markets. We remain dedicated to serving as a trusted partner to our US and international colleagues in advancing life sciences innovation through strategic patent protection and portfolio management.

Our President and Managing Director Ms. Jennifer Che traveled to Boston last week to accept the award on behalf of our entire team, as well as to speak at the LSPN two-day conference which preceded the awards ceremony.

We are truly honored to be named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026! This recognition is a testament to the hard work and dedication of our entire team. A heartfelt THANK YOU to our clients for your trust and support, to our incredible team for their continued pursuit of excellence, and to our partners for their collaboration.


Explore the full list of winners from this year’s LSPN Awards USA: https://awards.newton.media/lspnawards2026/en/page/2026-winners

Our Past Events

Recommended Insights

Patent Inventiveness in China: Why “Common Knowledge” Must Be Proven, Not Assumed

14 August 2026
A Case Study of the "Electronic Blackboard" Case, (2025) SPC Zhi Xing Zhong No. 286 I. Introduction In assessing inventive step for invention patents, determining whether a technical solution would have been “readily conceivable” to a person skilled in the art has long been one of the most disputed and uncertain aspects of the analysis. […]

IP Update: China’s Supreme People’s Court Issues First Public Decision Defining China’s Inventorship Standard

1 June 2026
In theory China's inventorship standard is similar to others around the world. An inventor is anyone who "makes creative contributions to the substantive features" of an invention. But what does this mean, and how does one apply this standard? Up to this point, this issue hasn't really been litigated much in China (at least according […]

Breaking News: China passes Fourth Amendment to the Chinese Patent Law

19 October 2020
After 12 years, the Fourth Amendment to the Chinese Patent Law has passed and will be in effect on 1 Jun 2021. After years of multiple draft amendments that moved in various directions, we FINALLY have some clarity on what patent protection is going to look like in China in the coming future. Many of […]

Connecting the Dots: China’s Evolving Standard for Numerical Sub-Range Amendments

22 July 2026
Managing global pharmaceutical or chemical portfolios requires navigating China’s notoriously rigid standards on the "same subject matter" requirement for priority and claim amendments. A recent invalidation decision (No. 588094) issued by the China National Intellectual Property Administration (CNIPA) concerning a pharmaceutical patent provides clarity on how numerical ranges and later added experimental data are evaluated […]
Top crossarrow-right